Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04361253 · ClinicalTrials.gov registry record · Phase 3
Evaluation of SARS-CoV-2 (COVID-19) Antibody-containing Plasma thErapy
A Phase 3 study, sponsored by Brigham and Women's Hospital.
- Terminated
- Registry status
- Phase 3
- Development phase
- 45
- Enrollment target
NCT04361253 is a Phase 3 study that was terminated before completion, run by Brigham and Women's Hospital. The registered enrollment target is 45 participants.
The verdict
NCT04361253, a Phase 3 study, was terminated before completion, sponsored by Brigham and Women's Hospital.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 45 participants
- Enrollment target
Study Summary
In this study, investigators will determine whether the early addition of HT-CCP to standard treatment improves the clinical outcome (as assessed by the Modified WHO Ordinal Scale) of patients with COVID-19 who are hospitalized but not yet in moderate or severe ARDS.
Interventions
- BIOLOGICAL High-Titer COVID-19 Convalescent Plasma (HT-CCP)
- BIOLOGICAL Standard Plasma (FFP)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2020-04-30 |
| Est. Completion | 2021-06-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04361253
The ClinicalTrials.gov registry entry for NCT04361253 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Brigham and Women's Hospital, which has 937 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which High-Titer COVID-19 Convalescent Plasma (HT-CCP) is the first listed.
NCT04361253 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04361253 about?
NCT04361253 is a clinical study titled "Evaluation of SARS-CoV-2 (COVID-19) Antibody-containing Plasma thErapy". In this study, investigators will determine whether the early addition of HT-CCP to standard treatment improves the clinical outcome (as assessed by the Modified WHO Ordinal Scale) of patients with COVID-19 who are hospitalized but not yet in moderate or severe ARDS.
What is the current status of trial NCT04361253?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 45 participants. The study started on 2020-04-30. Estimated completion is 2021-06-30.
What interventions are being tested in trial NCT04361253?
The interventions under investigation include: High-Titer COVID-19 Convalescent Plasma (HT-CCP) (BIOLOGICAL), Standard Plasma (FFP) (BIOLOGICAL).
Who is sponsoring clinical trial NCT04361253?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.